Vivek Kumar
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Co-authors
- Abhinav Chandra (9 shared papers)Mohit Garg (9 shared papers)Parita Soni (12 shared papers)Neha Chaudhary (5 shared papers)Charalampos S. Floudas (2 shared papers)Osama E. Rahma (2 shared papers)Atul B. Shinagare (1 shared paper)Helmut G. Rennke (1 shared paper)
- Journals
- Blood (2 papers)Frontiers in Oncology (2 papers)Journal of Prosthodontics (2 papers)Frontiers in Pharmacology (2 papers)BMC Cancer (2 papers)
- Partner nations
- United StatesIndiaChina
In The Last Decade
Vivek Kumar
57 papers receiving 1.2k citations
Vivek Kumar's Hit Papers
Peers
Comparison fields: 5 of 88
- Oncology 621
- Hepatology 94
- Genetics 104
- Pathology and Forensic Medicine 157
- Hematology 89
Countries citing papers authored by Vivek Kumar
This map shows the geographic impact of Vivek Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Kumar more than expected).
Fields of papers citing papers by Vivek Kumar
This network shows the impact of papers produced by Vivek Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Kumar. The network helps show where Vivek Kumar may publish in the future.
Co-authors
The 25 scholars most cited alongside Vivek Kumar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy Hit paper breakdown → | 2017 | 477 |
| 2 | 2020 | 111 | |
| 3 | 2020 | 65 | |
| 4 | 2019 | 47 | |
| 5 | 2017 | 32 | |
| 6 | 1999 | 28 | |
| 7 | 2020 | 25 | |
| 8 | 2018 | 24 | |
| 9 | 2020 | 23 | |
| 10 | 2019 | 22 | |
| 11 | 2015 | 20 | |
| 12 | 2018 | 20 | |
| 13 | 2021 | 18 | |
| 14 | 2020 | 18 | |
| 15 | 2018 | 18 | |
| 16 | 2020 | 16 | |
| 17 | 2011 | 16 | |
| 18 | 2017 | 16 | |
| 19 | 2018 | 15 | |
| 20 | 2017 | 15 |
About Vivek Kumar
Vivek Kumar is a scholar working on Oncology, Surgery, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Hematology, having authored 63 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (7 papers), Cancer Immunotherapy and Biomarkers (6 papers), Multiple Myeloma Research and Treatments (5 papers), Viral-associated cancers and disorders (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Polyomavirus and related diseases (2 papers), Cardiac tumors and thrombi (2 papers) and Reconstructive Facial Surgery Techniques (2 papers). The work is most often cited by research in Oncology (621 citations), Hepatology (94 citations), Genetics (104 citations), Pathology and Forensic Medicine (157 citations) and Hematology (89 citations). Vivek Kumar has collaborated with scholars based in United States, India and China. Frequent co-authors include Abhinav Chandra, Mohit Garg, Parita Soni, Neha Chaudhary, Charalampos S. Floudas, Osama E. Rahma, Atul B. Shinagare, Helmut G. Rennke, Jochen H. Lorch and Patrick A. Ott. Their work appears in journals such as Blood, Frontiers in Oncology, Journal of Prosthodontics, Frontiers in Pharmacology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.